$10.53
00.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Rigel Pharmaceuticals
RIGLNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock, Analyst Ratings, Price Targets, Forecasts
Rigel Pharmaceuticals Inc has a consensus price target of $4.32 based on the ratings of 7 analysts. The high is $15 issued by HC Wainwright & Co. on June 25, 2024. The low is $1.25 issued by B. Riley Securities on March 6, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on June 25, 2024, June 17, 2024, and June 3, 2024, respectively. With an average price target of $15 between HC Wainwright & Co., there's an implied 42.45% upside for Rigel Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Citigroup
Cantor Fitzgerald
B. Riley Securities
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Rigel Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/25/2024 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 06/17/2024 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 06/03/2024 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | $150 → $150 | Reiterates | Buy → Buy | Get Alert |
| 03/07/2024 | Buy Now | -62.01% | Citigroup | Yigal Nochomovitz | $30 → $40 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | -71.51% | Cantor Fitzgerald | Kristen Kluska | $20 → $30 | Maintains | Neutral | Get Alert |
| 03/06/2024 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | → $150 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | -88.13% | B. Riley Securities | Kalpit Patel | $12.5 → $12.5 | Maintains | Neutral | Get Alert |
| 02/22/2024 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | → $150 | Reiterates | Buy → Buy | Get Alert |
| 01/04/2024 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | → $150 | Reiterates | Buy → Buy | Get Alert |
| 12/08/2023 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | → $150 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | → $150 | Reiterates | Buy → Buy | Get Alert |
| 05/03/2023 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | → $150 | Reiterates | → Buy | Get Alert |
| 04/03/2023 | Buy Now | -81.01% | Piper Sandler | Allison Bratzel | → $20 | Assumes | → Neutral | Get Alert |
| 03/09/2023 | Buy Now | -71.51% | Citigroup | Yigal Nochomovitz | $20 → $30 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | → $150 | Reiterates | → Buy | Get Alert |
| 12/02/2022 | Buy Now | — | Citigroup | Yigal Nochomovitz | — | Upgrade | Neutral → Buy | Get Alert |
| 11/04/2022 | Buy Now | -71.51% | BMO Capital | Gary Nachman | $40 → $30 | Maintains | Outperform | Get Alert |
| 08/18/2022 | Buy Now | 42.45% | HC Wainwright & Co. | Joseph Pantginis | $70 → $150 | Maintains | Buy | Get Alert |
| 08/17/2022 | Buy Now | -81.01% | Piper Sandler | Do Kim | $10 → $20 | Maintains | Neutral | Get Alert |
| 06/09/2022 | Buy Now | -71.51% | BMO Capital | Gary Nachman | $70 → $30 | Maintains | Outperform | Get Alert |
| 06/09/2022 | Buy Now | -88.13% | B. Riley Securities | Kalpit Patel | $40 → $12.5 | Maintains | Neutral | Get Alert |
| 06/09/2022 | Buy Now | -92.4% | Citigroup | Yigal Nochomovitz | $70 → $8 | Downgrade | Buy → Neutral | Get Alert |
| 06/08/2022 | Buy Now | -33.52% | HC Wainwright & Co. | Joseph Pantginis | $110 → $70 | Maintains | Buy | Get Alert |
| 06/08/2022 | Buy Now | — | Cantor Fitzgerald | Kristen Kluska | — | Downgrade | Overweight → Neutral | Get Alert |
| 03/23/2022 | Buy Now | -62.01% | B. Riley Securities | Kalpit Patel | → $40 | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Rigel Pharmaceuticals (RIGL) stock?
The latest price target for Rigel Pharmaceuticals (NASDAQ:RIGL) was reported by HC Wainwright & Co. on June 25, 2024. The analyst firm set a price target for $15.00 expecting RIGL to rise to within 12 months (a possible 42.45% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rigel Pharmaceuticals (RIGL)?
The latest analyst rating for Rigel Pharmaceuticals (NASDAQ:RIGL) was provided by HC Wainwright & Co., and Rigel Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Rigel Pharmaceuticals (RIGL)?
The last upgrade for Rigel Pharmaceuticals Inc happened on December 2, 2022 when Citigroup raised their price target to N/A. Citigroup previously had a neutral for Rigel Pharmaceuticals Inc.
When was the last downgrade for Rigel Pharmaceuticals (RIGL)?
The last downgrade for Rigel Pharmaceuticals Inc happened on June 9, 2022 when Citigroup changed their price target from $7 to $0.8 for Rigel Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Rigel Pharmaceuticals (RIGL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rigel Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rigel Pharmaceuticals was filed on June 25, 2024 so you should expect the next rating to be made available sometime around June 25, 2025.
Is the Analyst Rating Rigel Pharmaceuticals (RIGL) correct?
While ratings are subjective and will change, the latest Rigel Pharmaceuticals (RIGL) rating was a reiterated with a price target of $15.00 to $15.00. The current price Rigel Pharmaceuticals (RIGL) is trading at is $10.53, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.